TY - JOUR
T1 - Benefit of surveillance for pancreatic cancer in high-risk individuals
T2 - Outcome of long-term prospective follow-up studies from three European expert centers
AU - Vasen, Hans
AU - Ibrahim, Isaura
AU - Robbers, Kristin
AU - Van Mil, Anneke M.
AU - Potjer, Thomas
AU - Bonsing, Bert A.
AU - Bergman, Wilma
AU - Wasser, Martin
AU - Morreau, Hans
AU - De Vos Tot Nederveen Cappel, Wouter H.
AU - Ponce, Carmen Guillen
AU - Carrato, Alfredo
AU - Earl, Julie
AU - Mocci, Evelina
AU - Vazquez-Sequeiros, Enrique
AU - Sanjuanbenito, Alfonso
AU - Muñoz-Beltran, Maria
AU - Montans, José
AU - Slater, Emily P.
AU - Matthäi, Elvira
AU - Fendrich, Volker
AU - Bartsch, Detlef K.
AU - Schicker, Christoph
AU - Steinkamp, Martin
AU - Figiel, Jens
AU - Klöppel, Günter
AU - Langer, Peter
AU - Esposito, Irene
N1 - Publisher Copyright:
© 2016 by American Society of Clinical Oncology.
PY - 2016/6/10
Y1 - 2016/6/10
N2 - Purpose: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. Hereditary factors play a role in the development of PDAC in 3% to 5% of all patients. Surveillance of high-risk groups, may facilitate detection of PDAC at an early stage. The aim of this study was to assess whether surveillance aids detection of early-stage PDAC or precursor lesions (PRLs) and improves the prognosis. Patients and Methods: Screening outcomes were collected from three European centers that conduct prospective screening in high-risk groups including families with clustering of PDAC (familial pancreatic cancer [FPC]) or families with a gene defect that predisposes to PDAC. The surveillance program consisted of annual magnetic resonance imaging, magnetic resonance cholangiopancreatography, and/or endoscopic ultrasound. Results: Four hundred eleven asymptomatic individuals participated in the surveillance programs, including 178 CDKN2A mutation carriers, 214 individuals with FPC, and 19 BRCA1/2 or PALB2 mutation carriers. PDAC was detected in 13 (7.3%) of 178 CDKN2A mutation carriers. The resection rate was 75%, and the 5-year survival rate was 24%. Two CDKN2A mutation carriers (1%) underwent surgical resection for low-risk PRL. Two individuals (0.9%) in the FPC cohort had a pancreatic tumor, including one advanced PDAC and one early grade 2 neuroendocrine tumor. Thirteen individualswith FPC (6.1%) underwent surgical resection for a suspected PRL, but only four (1.9%) had high-risk lesions (ie, high-grade intraductal papillary mucinous neoplasms or grade 3 pancreatic intraepithelial neoplasms). One BRCA2 mutation carrier was found to have PDAC, and another BRCA2 mutation carrier and a PALB2 mutation carrier underwent surgery and were found to have low-risk PRL. No serious complications occurred as consequence of the program. Conclusion: Surveillance of CDNK2A mutation carriers is relatively successful, detecting most PDACs at a resectable stage. The benefit of surveillance in families with FPC is less evident.
AB - Purpose: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. Hereditary factors play a role in the development of PDAC in 3% to 5% of all patients. Surveillance of high-risk groups, may facilitate detection of PDAC at an early stage. The aim of this study was to assess whether surveillance aids detection of early-stage PDAC or precursor lesions (PRLs) and improves the prognosis. Patients and Methods: Screening outcomes were collected from three European centers that conduct prospective screening in high-risk groups including families with clustering of PDAC (familial pancreatic cancer [FPC]) or families with a gene defect that predisposes to PDAC. The surveillance program consisted of annual magnetic resonance imaging, magnetic resonance cholangiopancreatography, and/or endoscopic ultrasound. Results: Four hundred eleven asymptomatic individuals participated in the surveillance programs, including 178 CDKN2A mutation carriers, 214 individuals with FPC, and 19 BRCA1/2 or PALB2 mutation carriers. PDAC was detected in 13 (7.3%) of 178 CDKN2A mutation carriers. The resection rate was 75%, and the 5-year survival rate was 24%. Two CDKN2A mutation carriers (1%) underwent surgical resection for low-risk PRL. Two individuals (0.9%) in the FPC cohort had a pancreatic tumor, including one advanced PDAC and one early grade 2 neuroendocrine tumor. Thirteen individualswith FPC (6.1%) underwent surgical resection for a suspected PRL, but only four (1.9%) had high-risk lesions (ie, high-grade intraductal papillary mucinous neoplasms or grade 3 pancreatic intraepithelial neoplasms). One BRCA2 mutation carrier was found to have PDAC, and another BRCA2 mutation carrier and a PALB2 mutation carrier underwent surgery and were found to have low-risk PRL. No serious complications occurred as consequence of the program. Conclusion: Surveillance of CDNK2A mutation carriers is relatively successful, detecting most PDACs at a resectable stage. The benefit of surveillance in families with FPC is less evident.
UR - http://www.scopus.com/inward/record.url?scp=84971659586&partnerID=8YFLogxK
U2 - 10.1200/JCO.2015.64.0730
DO - 10.1200/JCO.2015.64.0730
M3 - Article
C2 - 27114589
AN - SCOPUS:84971659586
SN - 0732-183X
VL - 34
SP - 2010
EP - 2019
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 17
ER -